Cadila share price rose 3.29% as the healthcare leader Cadila or Zydus Cadila has entered into a non-exclusive, royalty-free agreement with Medicines Patent Pool (MPP) for the universal production of Bristol-Myers Squibb's daclatasvir, a novel direct-acting antiviral (DAA). The medicine is proven to help cure multiple genotypes of the Hepatitis C Virus (HCV). The company said that the agreement sub-licenses Zydus to produce and sell daclatasvir in 112 low and middle-income countries. <a href="htt